These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

640 related items for PubMed ID: 22358132

  • 1. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM.
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [Abstract] [Full Text] [Related]

  • 2. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
    Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY.
    J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
    [Abstract] [Full Text] [Related]

  • 3. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [Abstract] [Full Text] [Related]

  • 4. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS.
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [Abstract] [Full Text] [Related]

  • 5. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J, Han T, Liu L, Li Y, Li J, Li Y, Xiao SX.
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [Abstract] [Full Text] [Related]

  • 7. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [Abstract] [Full Text] [Related]

  • 8. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, Yeon JE, Byun KS, Kim KH, Ji SI, Kim SO, Lee CH, Kwon SY.
    Antivir Ther; 2009 Sep; 14(7):985-93. PubMed ID: 19918102
    [Abstract] [Full Text] [Related]

  • 9. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC, He LL, Chen Q.
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [Abstract] [Full Text] [Related]

  • 10. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
    Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK.
    J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
    [Abstract] [Full Text] [Related]

  • 11. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F, Club Epatologi Ospedalieri (CLEO) Group.
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [Abstract] [Full Text] [Related]

  • 12. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N.
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [Abstract] [Full Text] [Related]

  • 13. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A, Jochum C, Canbay A, Schlaak J, Gerlich WH, Gerken G.
    Eur J Med Res; 2008 Oct 27; 13(10):472-5. PubMed ID: 19008175
    [Abstract] [Full Text] [Related]

  • 14. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
    Kang SH, Yim HJ, Kim HR, Kang K, Suh SJ, Lee HJ, Yoon EL, Kim JH, Seo YS, Yeon JE, Byun KS.
    J Clin Gastroenterol; 2014 Oct 27; 48(10):889-95. PubMed ID: 24440937
    [Abstract] [Full Text] [Related]

  • 15. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
    Ha M, Zhang G, Diao S, Lin M, Wu J, Sun L, She H, Shen L, Huang C, Shen W, Huang Z.
    Intern Med; 2012 Oct 27; 51(12):1509-15. PubMed ID: 22728482
    [Abstract] [Full Text] [Related]

  • 16. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H.
    J Hepatol; 2008 Jun 27; 48(6):923-31. PubMed ID: 18433925
    [Abstract] [Full Text] [Related]

  • 17. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH, Cho M, Yoon KT, Bae JH, Heo J, Kim GH, Kang DH, Song GA.
    Korean J Hepatol; 2008 Dec 27; 14(4):503-12. PubMed ID: 19119245
    [Abstract] [Full Text] [Related]

  • 18. Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
    Lee JH, Yoon JH, Cho EJ, Yang HJ, Jang ES, Kwak MS, Hwang SY, Yu SJ, Lee CH, Kim YJ, Kim CY, Lee HS.
    J Clin Gastroenterol; 2012 Mar 27; 46(3):243-50. PubMed ID: 21716122
    [Abstract] [Full Text] [Related]

  • 19. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H.
    J Med Virol; 2011 Jun 27; 83(6):953-61. PubMed ID: 21503906
    [Abstract] [Full Text] [Related]

  • 20. Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
    Yim HJ, Lee HJ, Suh SJ, Seo YS, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH.
    Intervirology; 2014 Jun 27; 57(5):239-47. PubMed ID: 24993731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.